SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PPARγ Ligand Pack

Item No. 71000

Laboratory Procedures

For long term storage, we suggest that the PPARγ Ligand Pack be stored as supplied at -20°C. It should be stable for at least one year. Each of the items in this kit are provided as crystalline solids and have a ≥98% purity, with the exception of 15-deoxy-$\Delta^{12,14}$-prostaglandin J_2 (15-deoxy-$\Delta^{12,14}$-PGJ_2) which is a 10 mg/ml solution in methyl acetate with a purity of ≥98% as a mixture of isomers. Please see the chart below for the amount included and solubility information for the items in this kit.

Description

The Cayman PPARγ Ligand Pack contains a combination of frequently used ligands for the nuclear PPARγ. Each kit contains Ciglitazone, the first characterized member of the thiazolidinedione (TZD) class that binds to the PPARγ ligand-binding domain with an EC_{50} value of 3.0 µM.[1,2] Rosiglitazone, a key reference TZD also called BRL 49653, its more potent structural homolog MCC-555, and PPARγ-1-selective pioglitazone are other PPARγ agonists provided. Also included is Troglitazone, another TZD; it was withdrawn from human therapeutic use due to hepatotoxicity.[3] Also in this assortment is 15-deoxy-$\Delta^{12,14}$-PGJ_2, a potent PPARγ ligand derived from PGD_2. The actions of all of these compounds can be antagonized by the selective PPARγ antagonist, GW 9662, which is also in the kit.[4]

Item No.	Component	Amount	Solubility
18570.1	15-deoxy-$\Delta^{12,14}$-PGJ_2	1 mg	>2.7 mg/ml in PBS (pH 7.2)
71730	Ciglitazone	5 mg	>0.4 mg/ml in DMSO:PBS (pH 7.2) (1:4)
70785	GW 9662	5 mg	>0.5 mg/ml in DMSO:PBS (pH 7.2) (1:1)
70735	MCC-555	1 mg	>1 mg/ml in DMSO:PBS (pH 7.2) (1:1)
71745	Pioglitazone	5 mg	>0.1 mg/ml in DMSO:PBS (pH 7.2) (1:1)
71740	Rosiglitazone	5 mg	>0.5 mg/ml in DMSO:PBS (pH 7.2) (1:3)
71750	Troglitazone	5 mg	>0.1 mg/ml in DMSO:PBS (pH 7.2) (1:6)

References

1. Willson, T.M., Cobb, J.E., Cowan, D.J., *et al.* The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. *J. Med. Chem.* **39**, 665-668 (1996).
2. Sohda,T., Mizuno,K., Imaniya,E., *et al.* Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methyl-cyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. *Chem. Pharm. Bull.* **30**(**10**), 3580-3600 (1982).
3. Kodera, Y., Takeyama, K., Murayama, A., *et al.* Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. *J. Biol. Chem.* **275**, 33201-33204 (2000).
4. Bendixen, A.C., Shevde, N.K., Dienger, K.M., *et al.* IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors *via* peroxisome proliferator-activated receptor γ1. *Proc. Natl. Acad. Sci. USA* **98**, 2443-2448 (2001).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM